Skip to main content

Enright Patrick G's Form 4 filing

Lexeo Therapeutics, Inc.LXEO · filed Nov 9, 2023

Accession no.
0001209191-23-054904
Filed
Nov 9, 2023, 8:32 PM ET
Trade date
Nov 7, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $5.00M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Enright Patrick GCIK 000125388610% Owner
Tammenoms Bakker JulietCIK 000143115910% Owner
Longitude Venture Partners IV, L.P.CIK 000178745610% Owner
Longitude Capital Partners IV, LLCCIK 000182916910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 7, 2023Common StockCConversionAcquired+1,793,429–F1–1,793,429Indirect
Nov 7, 2023Common StockCConversionAcquired+319,126–F3–2,112,555Indirect
Nov 7, 2023Common StockPPurchaseAcquired+454,545$11.00+$4,999,9952,567,100Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 7, 2023Common StockCConversionDisposed−1,793,429–F1–0Indirect
Nov 7, 2023Common StockCConversionDisposed−319,126–F3–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

F3

Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)